Cognition Therapeutics Inc (CGTX) - Total Liabilities
Based on the latest financial reports, Cognition Therapeutics Inc (CGTX) has total liabilities worth $6.87 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Cognition Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Cognition Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Cognition Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Cognition Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Cognition Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Cognition Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
|
Korea | ₩136.13 Billion |
|
Optex Systems Holdings, Inc. Common Stock
NASDAQ:OPXS
|
USA | $4.56 Billion |
|
Kapsch Traffic
VI:KTCG
|
Austria | €322.77 Million |
|
Empery Digital Inc.
NASDAQ:EMPD
|
USA | $51.74 Million |
|
Associated Capital Group Inc
NYSE:AC
|
USA | $38.70 Million |
|
Tan Chong Motor Holdings Bhd
KLSE:4405
|
Malaysia | RM2.21 Billion |
|
Borges Agricultural & Industrial Nuts S.A.
MC:BAIN
|
Spain | €43.20 Million |
|
Bluemount Holdings Limited Class B Ordinary Shares
NASDAQ:BMHL
|
USA | $23.08 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Cognition Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cognition Therapeutics Inc (CGTX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cognition Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cognition Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Cognition Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.48 Million | +7.44% |
| 2023-12-31 | $10.69 Million | +5.04% |
| 2022-12-31 | $10.18 Million | +29.40% |
| 2021-12-31 | $7.86 Million | -89.56% |
| 2020-12-31 | $75.30 Million | +14.30% |
| 2019-12-31 | $65.88 Million | -- |
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2… Read more